First-person chronicles
GLP-1 Diaries
Month-by-month first-person GLP-1 chronicles. Composite patient personas (anonymized + reviewed by an MD) with quantified weight + side-effect data each month. What the trial data looks like from inside the experience.
Wegovy Diary: a 6-month chronicle
Month 1 · −7 lb
Wegovy Diary Month 1: the first injection, peak nausea, food noise quiet
A composite first-month chronicle of starting Wegovy at 0.25 mg. What injection day actually feels like, when the food noise drops, and what hit me at week 3 that nobody warned me about.
Read this month
Month 2 · −6 lb
Wegovy Diary Month 2: the boring middle, first restaurant test, the scale catches up
Month 2 is when the routine settles. I'm at 0.5 mg, the food noise is permanently quieter, and I have my first real-restaurant test. The result surprised me.
Read this month
Month 3 · −5 lb
Wegovy Diary Month 3: 1.0 mg settles in, the friends-and-family question, body composition changes
Month 3 at 1.0 mg. The questions from people I haven't seen in a while start. I take my first DEXA scan and the body composition surprises me in a useful direction.
Read this month
Month 4 · −6 lb
Wegovy Diary Month 4: 1.7 mg dose, plateau scare, the social trip
Month 4 introduces 1.7 mg, my first scale plateau, and a 5-day work trip with restaurant meals every night. Here's how each tested the routine.
Read this month
Zepbound Diary: a 6-month chronicle
Month 1 · −7 lb
Zepbound Diary Month 1: starter dose, dual-receptor effect, the appetite shift
First month on Zepbound at 2.5 mg. The dual GIP/GLP-1 mechanism shows up differently — appetite doesn't just shut down, it shifts. Here's the unexpurgated month 1.
Read this month
Month 2 · −6 lb
Zepbound Diary Month 2: 5 mg therapeutic dose, the appetite settles, first 10 lb threshold
Month 2 on Zepbound at 5 mg. The dual-receptor effect compounds. I cross the first 10 lb threshold and start noticing the things that don't fit anymore.
Read this month
Composite-persona attribution: Each diary is a synthesized first-person account drawn from clinical trial cohorts + patient-reported outcome corpora. Every quantitative claim (weight loss, side-effect timing, doses) maps to FDA-label data and is reviewed by an MD before publication. Names are composites.